Latest research on Gefitinib

Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa. [Wikipedia]

Latest findings

In our example, Erlotinib and Gefitinib were frequently lumped together in EGFR TYROSINE kinase inhibitors and Docetaxel and Pemetrexed were lumped together in monochemotherapy. [source, 2016]
Subsequently, the patient started to receive Gefitinib tablet 250 mg once a day, which is a potent anticancer drug with reported efficacy in treating lung adenocarcinoma. [source, 2016]
EGFR is a target for several anticancer therapeutics, such as TYROSINE kinase inhibitors Gefitinib and Erlotinib and monoclonal antibodies cetuximab and panitumumab (3). [source, 2016]
Overexpression of EGFR can be used for stratification of patients with advanced NSCLC to Gefitinib (9,10) and to first-line chemotherapy in combination with cetuximab (11). [source, 2016]
Melanoma cancer cells can also switch from BRAF-dependence to CRAF-dependence in response to an RAF kinase inhibitor, namely, AZ628.8 Similar acquired resistance is explained by ERBB3–PI3K–AKT activation through MET amplification in non-small cell lung cancer, when treated with Gefitinib (an EGFR inhibitor). [source, 2016]
Global and regional phase III randomized-controlled trials demonstrated that the median progression-free survival (PFS) after Gefitinib or Erlotinib ranged from 9 to 13 months with the longest PFS of 13.1 months seen in OPTIMAL study using Erlotinib [1–7]. [source, 2016]
The LUX-Lung1 study published in 2010 has demonstrated efficacy with improvement in progression-free survival (3.3 months) for those who had taken afatinib 50 mg daily compared to those who had placebo, after previous treatment with Gefitinib or Erlotinib for at least 12 weeks and at least one line of platinum-based chemotherapy [13]. [source, 2016]
Patients who had EGFR-mutated metastatic NSCLC with prior documented objective response to first-generation TKI (Gefitinib or Erlotinib) for 6 months and prior treatment of at least 1 line of systemic chemotherapy were eligible to join the CUP offered by Boehringer-Ingelheim Pharma GmbH, Ingelheim, Germany. [source, 2016]
All these parameters of all patients in the afatinib group in this study were compared to a historical cohort of all patients who received Erlotinib after prior failure to Gefitinib and at least one line of systemic chemotherapy in our department from January 2009 to December 2011, with the same inclusion and exclusion criteria as for the patients who received afatinib in this study. [source, 2016]
Though first-generation EGFR-TKI with Gefitinib or Erlotinib has been the standard first-line treatment for metastatic EGFR-mutated NSCLC as demonstrated in various phase 3 randomized-controlled clinical trials [1–7], resistance against these first-generation TKI eventually develops after a median treatment duration of 9 to 13 months. [source, 2016]